MedWatch

Sobi receives FDA breakthrough designation for hemophilia drug

The US health authority has now awarded the Swedish firm three special statuses – the orphan drug, fast-track, and breakthrough therapy designations – for its hemophilia A treatment.

Photo: John Ambrose / Sobi / PR

Swedish biotech firm Sobi has been granted the US Food and Drug Administration’s (FDA) breakthrough therapy designation for its drug candidate, efanesoctocog alfa, a potential treatment for bleeding disorder hemophilia A, the company has announced in a press release.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs